IDWeek **2015 #786**

Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers (POICs)

Lucinda J. Van Anglen¹, PharmD, Robin H. Dretler, MD², Luu Quyen, MD³, Ramesh V. Nathan, MD, FIDSA⁴, Barry Statner, MD CM, FRCPC, FIDSA⁴, Fernando S. Alvarado, MD⁵

¹Healix Infusion Therapy, Inc., Sugar Land, TX; ²Infectious Disease Specialists of Atlanta, Atlanta, GA; ³Quyen Luu, MD, Macon, GA; ⁴Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA; ⁵Infectious Disease Consultants, Altamonte Springs, FL

Abstract, revised

Background: Dalbavancin (DAL), a long-acting lipoglycopeptide, was recently approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible grampositive bacteria. With weekly administration, this agent may be beneficial for use in outpatient parenteral antimicrobial therapy (OPAT). We report clinical experience of OPAT use of DAL. **Methods:** A multi-center, retrospective database review was conducted of all patients (pts) receiving DAL in 16 POICs from July 2014 through March 2015. Demographics, therapy

characteristics, microbiology, adverse events (AEs), clinical outcomes and recurrences were evaluated

Results: DAL was administered to 105 pts with 57 (54%) males and an overall mean age of 62 ± 16 years. Predominant diagnoses were cellulitis (45%), abscess (28%), osteomyelitis (12%), diabetic foot infection (11%) and implanted prosthetic device infection (4%). Forty nine pts (47%) had DAL therapy initiated in the POIC and 56 pts (53%) received DAL following hospitalization. Fifty-five pts (53%) received other intravenous antibiotics (IVABs) prior to treatment with DAL for a median of 5 days. Eighty seven pts (83%) received 2 doses of DAL, one week apart. Six pts (6%) received more than 2 doses. Infusions were administered by peripheral intravenous catheter in 84 pts (80%). Among 81 pts with available cultures, methicillin-resistant S. aureus was the most frequent pathogen (48%). Overall clinical success was reported in 88 of 105 pts (84%) with 52% cured and 32% improving. Reasons for failure included disease exacerbation in 6 pts (6%) and serious adverse events causing discontinuation of DAL in 10 pts (9%). Of these, 9 of 10 pts had hypersensitivity reactions following the first dose, the majority (67%) occurring in pts receiving other IVABs prior to DAL. Mild to moderate AEs were reported in 20 pts (19%), most commonly diarrhea (n=10), nausea (n=4), dizziness (n=4) and infusion site reactions (n=3). Disease recurrences within 60 days post DAL occurred in 7 of 82 evaluable pts (9%).

Conclusion: OPAT use of DAL in a physician office setting appears to be safe and effective. AEs were notable, including those requiring DAL discontinuation. The use of DAL may offer added safety and potential cost reductions in this setting due to avoidance of central line catheters. Additional studies are warranted.

Introduction

DAL is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.¹ It has been shown to be non-inferior to intravenous vancomycin followed with oral linezolid and has potent activity against a large majority of drug resistant S. aureus strains.² An advantage of DAL is its long half life which allows for once weekly dosing with a recommended 2 dose regimen consisting of 1000 mg followed by 500 mg one week later. This decreases treatment burden on pts and facilitates use in OPAT.

Currently, data in the literature are scarce regarding the real-world clinical use of DAL. The purpose of this study is to report a nationwide clinical experience of outpatient DAL use in a POIC setting.


Methods

A multi-center retrospective database and chart review was conducted to identify pts who received DAL at 16 POICs nationally from July 2014 through March 2015. Data collected included pt demographics, all treatment parameters including prior therapy, microbiology, regimen, AEs, clinical outcomes and recurrences.


- Descriptive statistics (mean, median) were used for demographics, microbiology, regimen, and outcome data.
- ✤ AEs were compared to clinical trial data using Chi-squared test to determine statistical significance with p < 0.05.
- Clinical outcomes were evaluated for all pts who completed therapy as follows:
 - Cured: resolution of signs/symptoms and no further treatment needed
- Improved: partial resolution of signs/symptoms, continued oral antibiotics - Failed: new or worsening of signs/symptoms
- Success rate (%) was defined as (cured + improved)/(total no. of pts)/100%.
- Pts were followed for up to 60 days after end of DAL treatment

Results


Demographics



Infection Classification



Microbiology





IDWeek **2015**

eristics (n=105)	No. (%)
nder, male	57 (54%)
e (years)	
an (range)	62 (19-92)
≥65	48 (46%)
norbidities	
pertension	58 (55%)
ascular disease	49 (47%)
Obesity	43 (41%)
etes mellitus	39 (37%)
Arthritis	35 (33%)
ry of cellulitis	33 (31%)
eoplasm	27 (26%)
atric disorder	18 (17%)
crine disorder	16 (15%)
testinal disorder	16 (15%)
Prior to Therapy	
me/POIC	49 (47%)
: Use Prior to DAL	
piotic naïve	13 (12%)
ABnaïve	50 (48%)
	o o o o o rio i diti o

✤ 78 pts (74%) had 3 or more comorbidities

 Other gram-positive included unspecified S. aureus (10%), coagulase-negative staphylococci (4%), enterococci (1%) ✤ 23% (n=24) pts had no culture data available





Treatment-Related AEs	POIC Study n=105 No. (%)	DISCOVER 1& n=652 No. (%)
Diarrhea	10 (9.5)	8 (1.2)
Hypersensitivity reaction	9 (8.6)	1 (0.2)
Rash	7 (6.7)	10 (1.5)
Pruritis	5 (4.8)	6 (0.9)
Dizziness	4 (3.8)	8 (1.2)
Nausea	4 (3.8)	27(4.1)
Fatigue	3 (2.9)	-
Pyrexia	3 (2.9)	8 (1.2)
Infusion Site Reaction	2 (1.9)	9 (1.4)
C. difficile-associated diarrhea	1 (0.9)	-
Pts with any AE	30 (28)	80 (12)
Total No. of AEs [†]	48 (46)	139 (21)
AEs leading to drug discontinuation	10 (9.5)	14 (2.1)

Discussion

This retrospective study described the outpatient use of DAL in POICs.

- POIC
- further studies.
- for diagnoses other than ABSSI.
- lipoglycopeptides.
- vs. non-naïve pts.

Conclusions

References

We acknowledge the assistance of Alex Ng, PharmD and Jason Xu in this study.

Lucinda J. Van Anglen, PharmD Healix Infusion Therapy, Inc. 14140 SW Fwy, Ste. 400 Sugar Land, TX 77478 281-295-4000 Lvananglen@healix.net

✤ Almost half of pts (47%) initiated therapy in the POIC. DAL was used as a first-line therapy in 13 pts (12%) naïve to antibiotics.

✤ DAL was successfully used in treating a variety of infections in the

✤ DAL was used successfully to treat prosthetic joint infections and osteomyelitis. Data on these diagnosis may provide background for

✤ Incidence of overall and certain AEs was significantly higher in this study than previously reported in clinical trials.¹ Possible contributing factors include: 88% of pts were antibiotic non-naïve, 15% of pts with AEs reported prior drug or latex allergies and 27% of pts were treated

Further investigation into the incidence of serious adverse events and hypersensitivity reactions is warranted. Characterizing those patients at higher risk will be beneficial for broader use of long-acting

DAL demonstrated an overall clinical success rate of 84%, with a 52%. cure rate and 32% improved status. Among infection classes, cellulitis had the highest success rate (87%) and osteomyelitis had the lowest rate (62%). Success rates did not differ significantly in antibiotic naïve

♦ Overall 60-day recurrence rate was low at 9% among evaluable pts.

✤ With once-weekly administration and strong bactericidal activity against MRSA, DAL can be an effective treatment option in the outpatient setting, particularly for patients who are not candidates for daily infusions or for self-administration of IV antibiotics.

✤ AEs were notable, with a higher rate of serious events than previously reported. Patients previously treated with IVABs and those with drug allergies may predispose pts to DAL adverse events and hypersensitivity. This study would suggest that close management of AEs during treatment is necessary for successful outcomes.

Further real-world studies can help establish DAL's place in therapy and provide additional information on safety parameters.

Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014; 370:2169-2179.

McCurdy SP, Jones RN, Mendes RE, et al. In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. Antimicrob Agents Chemother. 2015; 59(8):5007-5009.

October 7 – 11, 2015, San Diego, CA